1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 12,600 | 14,200 | 17.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Ascentage Pharma Group International reports 1H results | 1 | Seeking Alpha | ||
| ASCENTAGE PHARMA GROUP INTERNATIONAL ADR Aktie jetzt für 0€ handeln | |||||
| Do | ASCENTAGE (06855): VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME | - | HKEx | ||
| Do | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| Do | ASCENTAGE (06855): INTERIM REPORT 2026 | 1 | HKEx | ||
| 21.08. | Transcript: Ascentage Pharma Group H1 2026 Earnings Conference Call | 1 | Benzinga.com | ||
| 20.08. | Ascentage 1H 2026 slides: 29% revenue growth, 9 trials advance | 2 | Investing.com | ||
| 20.08. | Ascentage Pharma Group International GAAP EPS of -$0.32 beats by $0.23, revenue of $44.5M misses by $7.73M | 2 | Seeking Alpha | ||
| 20.08. | ASCENTAGE 1H26 Loss Widens to RMB817 million; No Interim Dividend | 1 | AASTOCKS | ||
| 20.08. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates | 370 | GlobeNewswire (Europe) | Revenue for the first half of 2026 increased 29% year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. Expanded executive leadership with appointments... ► Artikel lesen | |
| 20.08. | ASCENTAGE (06855): ANNOUNCEMENT OF UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 2 | HKEx | ||
| 13.08. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 05.08. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 05.08. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026 | 1 | GlobeNewswire (USA) | ||
| 05.08. | ASCENTAGE (06855): NOTICE OF BOARD MEETING | 2 | HKEx | ||
| 03.08. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer | 164 | GlobeNewswire (Europe) | ROCKVILLE, Md., Aug. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery... ► Artikel lesen | |
| 03.08. | ASCENTAGE (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA APPOINTS DR. FAICAL MIYARA AS CHIEF BUSINESS OFFICER AND JIM ZIEGLER AS CHIEF COMMERCIAL ... | 2 | HKEx | ||
| 27.07. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.07. | Wall Street Analysts Predict a 160.09% Upside in Ascentage Pharma Group International - Unsponsored ADR (AAPG): Here's What You Should Know | 1 | Zacks | ||
| 27.07. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026 | 1 | GlobeNewswire (USA) | ||
| 13.07. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings |
1 2 3 4 Weiter >>
76 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARIS LIFE SCIENCES | 27,200 | +10,57 % | Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance | Revenue growth of 45% driven by strong performance in molecular profiling services, including approximately 59,200 clinical cases, consisting of over 114,000 whole... ► Artikel lesen | |
| AKTIS ONCOLOGY | 22,800 | +1,74 % | Aktis Oncology Inc.: Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 | Presented first-in-human clinical imaging and dosimetry data for AKY-2519, supporting a broad clinical development program in patients with prostate, lung, and other B7-H3 expressing solid tumorsEnrolling... ► Artikel lesen | |
| PARABILIS MEDICINES | 40,880 | +10,85 % | Parabilis auf Morgan-Stanley-Konferenz: Umfassende Strategie für Beta-Catenin-Plattform | ||
| APIMEDS PHARMACEUTICALS US | 1,640 | 0,00 % | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | ||
| CG ONCOLOGY | 75,62 | +2,02 % | CG Oncology auf Morgan Stanley Konferenz: Pläne für Markteinführung, Daten und Skalierung | ||
| QIAGEN | 38,605 | +3,79 % | BERENBERG stuft QIAGEN NV auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Qiagen mit einem Kursziel von 40 Euro auf "Hold" belassen. Der Medizintechnik- und Life-Science-Sektor bleibe fundamental attraktiv, wie die... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 46,940 | +3,30 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,540 | 0,00 % | Recursion Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript | ||
| VERA THERAPEUTICS | 34,290 | +1,84 % | Vera Therapeutics Announces TRUTAKNA (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy | TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 26,470 | +12,59 % | Arcutis auf Morgan Stanley Konferenz: ZORYVE treibt Wachstumsoffensive voran | ||
| ERASCA | 15,360 | -5,48 % | Propanc Biopharma, Inc.: Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc. | ||
| SUMMIT THERAPEUTICS | 17,715 | +1,81 % | UBS reiterates Summit Therapeutics stock rating on trial data | ||
| BIOAFFINITY TECHNOLOGIES | 8,880 | 0,00 % | bioAffinity Technologies, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 310,74 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 42,740 | +1,26 % | Harmony Biosciences stellt auf Cantor-Konferenz erweiterte Wachstumsstrategie vor |
Das Unternehmen ASCENTAGE PHARMA GROUP INTERNATIONAL ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,78 % bei einem Aktienkurs von 12,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCENTAGE PHARMA GROUP INTERNATIONAL ADR finden Sie auf Wallstreet Online.